CRSP
Price
$68.14
Change
+$2.21 (+3.35%)
Updated
Jul 23 closing price
Capitalization
5.88B
18 days until earnings call
MRNA
Price
$34.67
Change
+$1.94 (+5.93%)
Updated
Jul 23 closing price
Capitalization
13.41B
8 days until earnings call
Interact to see
Advertisement

CRSP vs MRNA

Header iconCRSP vs MRNA Comparison
Open Charts CRSP vs MRNABanner chart's image
CRISPR Therapeutics AG
Price$68.14
Change+$2.21 (+3.35%)
Volume$3.79M
Capitalization5.88B
Moderna
Price$34.67
Change+$1.94 (+5.93%)
Volume$12.5M
Capitalization13.41B
CRSP vs MRNA Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. MRNA commentary
Jul 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Buy and MRNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 24, 2025
Stock price -- (CRSP: $68.14 vs. MRNA: $34.67)
Brand notoriety: CRSP: Not notable vs. MRNA: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 117% vs. MRNA: 113%
Market capitalization -- CRSP: $5.88B vs. MRNA: $13.41B
CRSP [@Biotechnology] is valued at $5.88B. MRNA’s [@Biotechnology] market capitalization is $13.41B. The market cap for tickers in the [@Biotechnology] industry ranges from $295.06B to $0. The average market capitalization across the [@Biotechnology] industry is $2.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileMRNA’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • MRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, MRNA is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while MRNA’s TA Score has 6 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 4 bearish.
  • MRNA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MRNA is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а +23.58% price change this week, while MRNA (@Biotechnology) price change was +8.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.15%. For the same industry, the average monthly price growth was +22.17%, and the average quarterly price growth was +31.45%.

Reported Earning Dates

CRSP is expected to report earnings on Oct 29, 2025.

MRNA is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+8.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRNA($13.4B) has a higher market cap than CRSP($5.89B). CRSP YTD gains are higher at: 73.120 vs. MRNA (-16.619). CRSP has higher annual earnings (EBITDA): -455.24M vs. MRNA (-3.2B). MRNA has more cash in the bank: 5.98B vs. CRSP (1.86B). CRSP has less debt than MRNA: CRSP (219M) vs MRNA (745M). MRNA has higher revenues than CRSP: MRNA (3.14B) vs CRSP (35M).
CRSPMRNACRSP / MRNA
Capitalization5.89B13.4B44%
EBITDA-455.24M-3.2B14%
Gain YTD73.120-16.619-440%
P/E RatioN/AN/A-
Revenue35M3.14B1%
Total Cash1.86B5.98B31%
Total Debt219M745M29%
FUNDAMENTALS RATINGS
CRSP vs MRNA: Fundamental Ratings
CRSP
MRNA
OUTLOOK RATING
1..100
8418
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9496
PRICE GROWTH RATING
1..100
3653
P/E GROWTH RATING
1..100
802
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRNA's Valuation (60) in the Biotechnology industry is in the same range as CRSP (68). This means that MRNA’s stock grew similarly to CRSP’s over the last 12 months.

MRNA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that MRNA’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as MRNA (96). This means that CRSP’s stock grew similarly to MRNA’s over the last 12 months.

CRSP's Price Growth Rating (36) in the Biotechnology industry is in the same range as MRNA (53). This means that CRSP’s stock grew similarly to MRNA’s over the last 12 months.

MRNA's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for CRSP (80). This means that MRNA’s stock grew significantly faster than CRSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPMRNA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
68%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
N/A
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
84%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEGRX78.890.81
+1.04%
First Eagle Global R6
EXOSX36.44N/A
N/A
Manning & Napier Overseas Series I
RRRAX22.09N/A
N/A
DWS RREEF Real Estate Securities A
TRHBX24.15N/A
N/A
Nuveen Small Cap Blend Idx I
SBHCX12.47N/A
N/A
Segall Bryant & Hamill Small Cap Cre Ret

MRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with ARCT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRNA
1D Price
Change %
MRNA100%
+5.93%
ARCT - MRNA
51%
Loosely correlated
+6.33%
BNTX - MRNA
47%
Loosely correlated
+2.84%
NVAX - MRNA
46%
Loosely correlated
+8.59%
CRSP - MRNA
46%
Loosely correlated
+3.35%
ALLO - MRNA
45%
Loosely correlated
+16.90%
More